- Home
- VSEC vs PTGX Comparison
VSEC vs PTGX Comparison
Compare VSEC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSEC
- PTGX
- Stock Information
- Founded
- VSEC 1959
- PTGX 2006
- Country
- VSEC United States
- PTGX United States
- Employees
- VSEC N/A
- PTGX N/A
- Industry
- VSEC Military/Government/Technical
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- VSEC Consumer Discretionary
- PTGX Health Care
- Exchange
- VSEC Nasdaq
- PTGX Nasdaq
- Market Cap
- VSEC 3.2B
- PTGX 3.7B
- IPO Year
- VSEC N/A
- PTGX 2016
- Fundamental
- Price
- VSEC $172.66
- PTGX $62.14
- Analyst Decision
- VSEC Strong Buy
- PTGX Strong Buy
- Analyst Count
- VSEC 4
- PTGX 9
- Target Price
- VSEC $145.00
- PTGX $70.44
- AVG Volume (30 Days)
- VSEC 196.5K
- PTGX 948.7K
- Earning Date
- VSEC 11-04-2025
- PTGX 11-06-2025
- Dividend Yield
- VSEC 0.24%
- PTGX N/A
- EPS Growth
- VSEC 31.62
- PTGX N/A
- EPS
- VSEC 0.95
- PTGX 0.80
- Revenue
- VSEC $1,253,105,000.00
- PTGX $209,180,000.00
- Revenue This Year
- VSEC $2.95
- PTGX N/A
- Revenue Next Year
- VSEC $14.66
- PTGX $248.17
- P/E Ratio
- VSEC $52.20
- PTGX $76.66
- Revenue Growth
- VSEC 52.47
- PTGX N/A
- 52 Week Low
- VSEC $80.61
- PTGX $33.31
- 52 Week High
- VSEC $174.48
- PTGX $62.17
- Technical
- Relative Strength Index (RSI)
- VSEC 61.52
- PTGX 62.68
- Support Level
- VSEC $163.65
- PTGX $57.90
- Resistance Level
- VSEC $169.63
- PTGX $60.40
- Average True Range (ATR)
- VSEC 5.31
- PTGX 2.48
- MACD
- VSEC -0.23
- PTGX 0.09
- Stochastic Oscillator
- VSEC 88.41
- PTGX 99.22
About VSEC VSE Corporation
VSE Corp is a diversified aftermarket products and services company providing repair services, parts distribution, logistics, supply chain management, and consulting services for land, sea, and air transportation assets to commercial and government markets. Its operations include supply chain management solutions, parts supply and distribution, and maintenance, repair, and overhaul (MRO) services for vehicle fleet, aviation, maritime and other customers. Its reportable segments are; Aviation and Fleet. The majority of the revenue for the company is generated from the Aviation segment which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.